The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”) hereby informs, with reference to the current report number 22/2022 dated August 2, 2022,  that on October 3, 2022, its subsidiary Selvita d.o.o. received a purchase order expanding the scope of existing cooperation under a framework of Research Service Agreement dated 16th of July 2015, amended as of 18th July 2022 (“Order”), concluded between the Company together with its subsidiaries and one of the largest pharmaceutical capital groups in Europe (“Client”).

Under the Order the Company shall provide ADME/DMPK services including physicochemical profiling and analytical services to the Client that will support its research programs.

The Order’s increase will raise the estimated value of the Order by the amount of EUR 1,400,000 (PLN 6,758,080 at the exchange rate of EUR 1 = PLN 4.8272) to the total amount of EUR 3,600,000 (PLN 17,377,920 at an exchange rate of 1 EUR = 4.8272 PLN).

The total value of services provided by Selvita Capital Group to the Client’s capital group companies during the eight months of 2022 amounted to EUR 2,727,134 (PLN 13,164,419 converted at the exchange rate of 1 EUR = 4.8272 PLN).

Taking into account the value of the Order’s increase, as well as the fact of expansion of the cooperation between the Client and the Company, the Company’s Management Board considers the expanded Order to be important for the implementation of the Selvita Group’s long-term plans aimed at building a strong position as a leading service provider in the area of drug discovery project support.

Legal basis:
Art. 17.1 MAR

Representatives of the Company:     

  • Bogusław Sieczkowski – President of the Management Board
  • Miłosz Gruca – Vicepresident of the Management Member